Ibutilide (Fumarate)

Drug #1466

Ibutilide (Fumarate) is a substituted methane sulfonamide derivative, belongs to class III antiarrhythmic. Ibutilide (Fumarate) is indicated for rapid conversion of atrial fibrillation or atrial flutter to normal sinus rhythm. Ibutilide (Fumarate) is approved by FDA in December 28, 1995.

← Previous drug Next drug →

Primary Characteristics

It is of Synthetic origin and belongs to Methanesulfonamide.

Molecular Weight: 884 · pK_a: 8.4, 9.6 · Solubility in Water: >1 in 10 · Solubility in Alcohol: >1 in 4 · Non-proprietary name: Ibutilide (Fumarate).

Molecular structure of Ibutilide (Fumarate)

Pharmacokinetics

Absorption: Ibutilide (Fumarate) has an oral bioavailability is 41% (±41%), pre-systemic (first-pass) metabolism accounts for 45% (±45%).

Distribution: Ibutilide (Fumarate) has a volume of distribution is 11-15 l/kg. plasma protein binding is 40 %.

Elimination: it is metabolised via Hepatic, plasma half-life is 2-12 hr, renal excretion is 5-10% (unchanged).

Indications

Ibutilide (Fumarate) is primarily indicated in conditions like Atrial fibrillation, Atrial flutter, Ventricular tachycardia.

Contraindications

Ibutilide (Fumarate) is contraindicated in conditions like Hypersensitivity, Pregnancy, Ventricular tachyarrhythmias, Torsade de pointes.

Dosage

Ibutilide (Fumarate)'s dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
0.01 ml/kg	0.01 ml/kg	—	IV	For less than <60 kg. If the arrhythmia does not terminate within 10 min after the end of the initial infusion, a second 10 min infusion of equal strength may be administered 10 min after completion of the first
1 mg	1 mg	—	IV	For >60 kg. If the arrhythmia does not terminate within 10 min after the end of the initial infusion, a second 10 min infusion of equal strength may be administered 10 min after completion of the first
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

1 interaction

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Ibutilide (Fumarate) in overdosage may give rise to further complications which include Sinus tachycardia , Hypertension , Torsades de pointes, QT prolongation.

Ibutilide (Fumarate) produces potentially life-threatening effects which include Polymorphic ventricular tachycardia. Careful monitoring is needed with proper medical management.

The signs and symptoms that are produced after acute overdosage of Ibutilide (Fumarate) are Heart block, Ventricular ectopy, Polymorphic ventricular tachycardia.

Ibutilide (Fumarate) is known to cause more or less tolerable side effects which are usually transient. These include AV Block , Congestive heart failure, Diarrhea, Dizziness, Headache, Hypotension , Idioventricular rhythm, Nausea, Nodal arrhythmias, Renal failure, Sinus bradycardia, Supraventricular tachycardia.

Warnings / Precautions

The ECG should be monitored continuously during infusion and for at least 4 hours after administration. The infusion should be stopped as soon as the arrhythmia is terminated.

Interference in Pathology

Ibutilide (Fumarate) may interfere in the diagnosis of None well documented.

Available Brands

None recorded.

Storage Conditions

Ibutilide (Fumarate) should be stored Inj.

Drug Classification

1.12.2 — Antiarrhythmic drugs